Phreesia Stock Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 42 minutes ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiff by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- How to Participate: Investors can join the class action by visiting https://rosenlegal.com/cases/phreesia-inc/join or calling Phillip Kim, Esq. at 866-767-3653 for information, with no upfront fees required.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.450
Low
24.00
Averages
29.09
High
35.00
Current: 9.450
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Reports Q1 Fiscal 2027 Earnings Highlights
- Revenue Growth: Phreesia reported Q1 revenue of $130.9 million, a 13% year-over-year increase, with Payment Solutions leading at 40% growth, indicating strong performance in the healthcare payment sector and potential for increased market share.
- New Financing Arrangement: The company successfully completed a $275 million senior secured revolving credit facility, using $92 million to repay its bridge loan, enhancing financial flexibility and providing capital for future expansion and investments.
- Client Growth: The average number of healthcare services clients reached 4,708 in Q1, an increase of 50 from the prior quarter and a 7% year-over-year growth, demonstrating effective strategies in client acquisition and retention.
- Improved Profitability: Adjusted EBITDA was $30.5 million, significantly up from $20.8 million in the prior year, with an EBITDA margin of 23%, reflecting ongoing improvements in cost control and operational efficiency.
See More
Phreesia Stock Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiff by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- How to Participate: Investors can join the class action by visiting https://rosenlegal.com/cases/phreesia-inc/join or calling Phillip Kim, Esq. at 866-767-3653 for information, with no upfront fees required.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. is accused of misleading investors from May 8, 2025, to March 30, 2026, by claiming reliable long-term growth prospects, while the uncertainty of its pharmaceutical marketing commitments jeopardizes the 2027 revenue target.
- Sportradar Violations: Sportradar Group AG faces allegations from November 7, 2024, to April 21, 2026, of collaborating with black-market gambling operators, undermining its claims of strict legal compliance and rendering its positive business outlook misleading.
- Commvault Sales Issues: Commvault Systems Inc. is accused of failing to disclose the impact of sales types on its annual recurring revenue (ARR) growth from April 29, 2025, to January 26, 2026, leading to misleading statements about its business prospects.
- Veritone Financial Misconduct: Veritone, Inc. is charged with inaccurately recording and misclassifying revenue from October 14, 2025, to April 14, 2026, necessitating a restatement of financial statements and severely impacting investor confidence in its financial health.
See More
Faruqi & Faruqi Encourages Phreesia Investors to Reach Out
- Legal Investigation: Faruq & Faruq LLP is investigating potential claims against Phreesia, Inc., particularly urging investors who purchased securities between May 8, 2025, and March 30, 2026, to seek lead plaintiff status by the July 13, 2026 deadline.
- False Statement Allegations: The lawsuit alleges that Phreesia and its executives violated federal securities laws by making false and misleading statements while failing to disclose the true state of slowing demand and reduced pharmaceutical marketing commitments, leading investors to purchase securities at inflated prices.
- Significant Stock Decline: Following Phreesia's announcement of drastically reduced revenue growth projections for fiscal year 2027 on March 30, 2026, the stock price plummeted from $11.41 per share to $8.38 per share, a decline of approximately 27%, indicating market pessimism regarding the company's future.
- Swift Investor Reaction: Investors and analysts reacted quickly to Phreesia's revenue warning, reflecting concerns about the company's growth potential, while Faruq & Faruq LLP encourages anyone with information to contact them to support the potential class action lawsuit.
See More
Phreesia Investors Alert: Lawsuit Deadline Approaches
- Lawsuit Notification: The Law Offices of Howard G. Smith remind investors that July 13, 2026, is the deadline to file a lead plaintiff motion in the class action lawsuit for those who purchased Phreesia (NYSE:PHR) stock between May 8, 2025, and March 30, 2026.
- Stock Price Plunge: Following the announcement on March 30, 2026, of significantly lowered revenue growth projections for fiscal 2027, Phreesia's stock price fell by $3.03, or 26.6%, closing at $8.38 per share on March 31, 2026, resulting in substantial losses for investors.
- False Representation Allegations: The lawsuit alleges that throughout the class period, defendants misled investors by projecting confidence in the company's long-term growth outlook while downplaying risks associated with slowing growth in its Network Solutions segment, thus jeopardizing the 2027 revenue targets.
- Participation Instructions: Investors who acquired Phreesia stock during the class period may move to appoint themselves as lead plaintiff by July 13, 2026, and the law firm offers consultations to help investors understand their legal rights and options.
See More
Commvault Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating claims on behalf of Commvault Systems, Inc. shareholders regarding potential breaches of fiduciary duties by executives, which could lead to corporate reforms and fund recovery for shareholders.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through executives' materially false and misleading statements, failing to disclose crucial variables affecting projected ARR growth for fiscal year 2026, potentially resulting in investor losses.
- Opportunity for Legal Action: Shareholders holding Commvault shares can seek court-approved incentive awards at no cost, highlighting the potential impact of governance issues on shareholder rights and corporate accountability.
- Potential Market Reaction Risks: Due to misleading expectations regarding ARR growth, Commvault's financial health may have been significantly overstated, posing risks of stock price declines and a crisis of investor confidence in the future.
See More
Phreesia Reports Q1 Fiscal 2027 Earnings Highlights
- Revenue Growth: Phreesia reported Q1 revenue of $130.9 million, a 13% year-over-year increase, with Payment Solutions leading at 40% growth, indicating strong performance in the healthcare payment sector and potential for increased market share.
- New Financing Arrangement: The company successfully completed a $275 million senior secured revolving credit facility, using $92 million to repay its bridge loan, enhancing financial flexibility and providing capital for future expansion and investments.
- Client Growth: The average number of healthcare services clients reached 4,708 in Q1, an increase of 50 from the prior quarter and a 7% year-over-year growth, demonstrating effective strategies in client acquisition and retention.
- Improved Profitability: Adjusted EBITDA was $30.5 million, significantly up from $20.8 million in the prior year, with an EBITDA margin of 23%, reflecting ongoing improvements in cost control and operational efficiency.
See More
Phreesia Stock Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiff by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- How to Participate: Investors can join the class action by visiting https://rosenlegal.com/cases/phreesia-inc/join or calling Phillip Kim, Esq. at 866-767-3653 for information, with no upfront fees required.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. is accused of misleading investors from May 8, 2025, to March 30, 2026, by claiming reliable long-term growth prospects, while the uncertainty of its pharmaceutical marketing commitments jeopardizes the 2027 revenue target.
- Sportradar Violations: Sportradar Group AG faces allegations from November 7, 2024, to April 21, 2026, of collaborating with black-market gambling operators, undermining its claims of strict legal compliance and rendering its positive business outlook misleading.
- Commvault Sales Issues: Commvault Systems Inc. is accused of failing to disclose the impact of sales types on its annual recurring revenue (ARR) growth from April 29, 2025, to January 26, 2026, leading to misleading statements about its business prospects.
- Veritone Financial Misconduct: Veritone, Inc. is charged with inaccurately recording and misclassifying revenue from October 14, 2025, to April 14, 2026, necessitating a restatement of financial statements and severely impacting investor confidence in its financial health.
See More
Faruqi & Faruqi Encourages Phreesia Investors to Reach Out
- Legal Investigation: Faruq & Faruq LLP is investigating potential claims against Phreesia, Inc., particularly urging investors who purchased securities between May 8, 2025, and March 30, 2026, to seek lead plaintiff status by the July 13, 2026 deadline.
- False Statement Allegations: The lawsuit alleges that Phreesia and its executives violated federal securities laws by making false and misleading statements while failing to disclose the true state of slowing demand and reduced pharmaceutical marketing commitments, leading investors to purchase securities at inflated prices.
- Significant Stock Decline: Following Phreesia's announcement of drastically reduced revenue growth projections for fiscal year 2027 on March 30, 2026, the stock price plummeted from $11.41 per share to $8.38 per share, a decline of approximately 27%, indicating market pessimism regarding the company's future.
- Swift Investor Reaction: Investors and analysts reacted quickly to Phreesia's revenue warning, reflecting concerns about the company's growth potential, while Faruq & Faruq LLP encourages anyone with information to contact them to support the potential class action lawsuit.
See More
Phreesia Investors Alert: Lawsuit Deadline Approaches
- Lawsuit Notification: The Law Offices of Howard G. Smith remind investors that July 13, 2026, is the deadline to file a lead plaintiff motion in the class action lawsuit for those who purchased Phreesia (NYSE:PHR) stock between May 8, 2025, and March 30, 2026.
- Stock Price Plunge: Following the announcement on March 30, 2026, of significantly lowered revenue growth projections for fiscal 2027, Phreesia's stock price fell by $3.03, or 26.6%, closing at $8.38 per share on March 31, 2026, resulting in substantial losses for investors.
- False Representation Allegations: The lawsuit alleges that throughout the class period, defendants misled investors by projecting confidence in the company's long-term growth outlook while downplaying risks associated with slowing growth in its Network Solutions segment, thus jeopardizing the 2027 revenue targets.
- Participation Instructions: Investors who acquired Phreesia stock during the class period may move to appoint themselves as lead plaintiff by July 13, 2026, and the law firm offers consultations to help investors understand their legal rights and options.
See More
Commvault Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating claims on behalf of Commvault Systems, Inc. shareholders regarding potential breaches of fiduciary duties by executives, which could lead to corporate reforms and fund recovery for shareholders.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through executives' materially false and misleading statements, failing to disclose crucial variables affecting projected ARR growth for fiscal year 2026, potentially resulting in investor losses.
- Opportunity for Legal Action: Shareholders holding Commvault shares can seek court-approved incentive awards at no cost, highlighting the potential impact of governance issues on shareholder rights and corporate accountability.
- Potential Market Reaction Risks: Due to misleading expectations regarding ARR growth, Commvault's financial health may have been significantly overstated, posing risks of stock price declines and a crisis of investor confidence in the future.
See More
